

## MEDICAL POLICY

|                      |                                 |
|----------------------|---------------------------------|
| <b>POLICY TITLE</b>  | <b>EVOKED POTENTIAL STUDIES</b> |
| <b>POLICY NUMBER</b> | <b>MP 4.029</b>                 |

|                         |   |
|-------------------------|---|
| <b>CLINICAL BENEFIT</b> | <input type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN.<br><input checked="" type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS.<br><input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE.<br><input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS.<br><input type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET.<br><input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE. |
| <b>Effective Date:</b>  | <b>4/1/2026</b>   |

**Note:** For intraoperative monitoring refer to **MP 2.030 Intraoperative Neurophysiologic Monitoring (Sensory-Evoked Potentials, Motor-Evoked Potentials, EEG Monitoring)**

### POLICY

Somatosensory Evoked Potentials may be considered **medically necessary** for the following indications:

- Evaluation of spinal cord lesions secondary to trauma, demyelinating disease, infection, or tumor; or
- To localize the cause of a central nervous deficit documented on exam, but not explained by MRI or CT; or
- To evaluate persons with suspected brain death.

Visual Evoked Potentials may be considered **medically necessary** for the following indications:

- To aid in the diagnosis and monitoring of multiple sclerosis (MS). Recordings made in the acute phase of MS disclose the presence of active, demyelinating plaques. Recordings made in the chronic phase of MS indicate the presence of subclinical plaques; or
- To localize the basis for visual field defects occurring in the absence of structural lesions, acquired metabolic disease, or infectious disease.

The use of visual evoked potentials is considered **investigational** for all other indications not listed in the policy, including evaluation for glaucoma. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

The nonoperative use of somatosensory-evoked potentials are considered **investigational** for all other indications not listed in the policy. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

***Cross-Reference:***

**MP 2.030 Intraoperative Neurophysiologic Monitoring (Sensory-Evoked Potentials, Motor-Evoked Potentials, EEG Monitoring)**

**MEDICAL POLICY**

|                      |                                 |
|----------------------|---------------------------------|
| <b>POLICY TITLE</b>  | <b>EVOKED POTENTIAL STUDIES</b> |
| <b>POLICY NUMBER</b> | <b>MP 4.029</b>                 |

**PRODUCT VARIATIONS**

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations. Please see additional information below.

**FEP PPO-** Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

**DESCRIPTION/BACKGROUND**

Evoked potential studies are tests that measure electrical activity or conduction velocities in the central nervous system in response to stimulation of sight, sound, or touch using computerized averaging techniques. These tests are useful in providing information to assist in diagnosing a pathological process and to identify neurological compromise during operative procedures. Three types of evoked potentials include somatosensory evoked potentials (SSEPs), visual evoked potentials (VEP), and brainstem auditory evoked potentials (BAEPs). These tests can be performed as outpatient diagnostic testing or inpatient for intraoperative monitoring.

Somatosensory evoked potentials (SSEPs) test is useful for diagnosing problems with the spinal cord as well as numbness and weakness of the extremities. During this test, electrodes are attached to the wrist, the back of the knee, or other locations, and a mild electrical stimulus is applied through the electrodes. Scalp electrodes then determine the amount of time it takes for the current to travel along the nerve to the brain.

Visual evoked potentials (VEP) test is used to diagnose problems with delays in the conduction of visual pathways, which may result from the demyelization effects of multiple sclerosis. During this test, electrodes are placed along the scalp, a checkerboard pattern flashes for several minutes on a screen, and electrical responses in the brain are recorded.

**RATIONALE**

**Visual Evoked Potentials for Glaucoma**

One small industry supported prospective study was carried out at the New York Eye and Ear Infirmary. Forty-five eyes of 35 patients with glaucomatous optic neuropathy and characteristic glaucomatous visual field (VF) defects were prospectively enrolled. Thirty healthy subjects with normal VF and normal intraocular pressure (IOP < 22 mm Hg) were enrolled. All patients underwent a complete ophthalmologic examination and had clear media, best corrected visual acuity (BCVA) ≥ 20/30, and pupil diameters > 3 mm and symmetric. Subjects with ocular diseases other than glaucoma, diabetes, or neurological disease were excluded. Glaucoma patients were recruited to be tested at their normally scheduled examination. The study indicated that the SD-tVEP fixed protocol's VEP responses to high- and low-contrast stimulus

**MEDICAL POLICY**

|                      |                                 |
|----------------------|---------------------------------|
| <b>POLICY TITLE</b>  | <b>EVOKED POTENTIAL STUDIES</b> |
| <b>POLICY NUMBER</b> | <b>MP 4.029</b>                 |

were able to detect retinal ganglion cells (RGC) function. In addition, the SD-tVEP P100's low-contrast latency and high-contrast amplitude response's sensitivity and specificity remained the same or increased with the progression of RGC damage. Since this study found strong discrimination between healthy and glaucomatous eyes, and since not all glaucoma patients or patients with other diseases of the optic nerve are under the care of a specialist, the fixed protocol was listed as a test which may be beneficial as a singular test in the early detection or diagnosis of such diseases. Further studies are warranted to determine if modifications to the present protocol could better isolate the M and P pathways VEP responses.

**Practice Guidelines and Position Statements**

The current National Institute for Health and Care Excellence (NICE) Guidance for the diagnosis and management of glaucoma issued November 2017 did not offer support for the use of visual evoked potential studies for the diagnostic evaluation for glaucoma.

The International Glaucoma Association does not make a recommendation on the use of VEP for the evaluation of glaucoma.

**Summary**

The absence of NICE guidance and other specialty society recommendations at this time is insufficient to support the use of visual evoked potential (VEP) studies for the evaluation of glaucoma. Therefore, the use of VEP in the evaluation of glaucoma is considered investigational.

**DEFINITIONS**

**DEMYELINATE** is to destroy or remove the myelin sheath of a nerve fiber as through disease.

**DISCLAIMER**

*Capital Blue Cross' medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as permitted by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member's benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members' benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross' Provider Services or Member Services.*

## MEDICAL POLICY

|                      |                                 |
|----------------------|---------------------------------|
| <b>POLICY TITLE</b>  | <b>EVOKED POTENTIAL STUDIES</b> |
| <b>POLICY NUMBER</b> | <b>MP 4.029</b>                 |

### CODING INFORMATION

**Note:** This list of codes may not be all inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

**Visual Evoked Potential screenings and testing for glaucoma is considered Investigational; therefore, not covered:**

| Procedure Codes |       |  |  |  |  |  |  |
|-----------------|-------|--|--|--|--|--|--|
| 0333T           | 0464T |  |  |  |  |  |  |

**Covered when medically necessary Somatosensory Evoked Potentials:**

| Procedure Codes |       |       |       |  |  |  |  |
|-----------------|-------|-------|-------|--|--|--|--|
| 95925           | 95926 | 95927 | 95938 |  |  |  |  |

| ICD-10-CM Diagnosis Codes | Description  |
|---------------------------|--|
| A52.13                    | Late syphilitic meningitis   |
| A52.14                    | Late syphilitic encephalitis   |
| A52.15                    | Late syphilitic neuropathy   |
| A52.17                    | General paresis  |
| A52.19                    | Other symptomatic neurosyphilis  |
| A69.21                    | Meningitis due to Lyme disease   |
| A69.22                    | Other neurologic disorders in Lyme disease                               |
| A69.23                    | Arthritis due to Lyme disease  |
| A69.29                    | Other conditions associated with Lyme disease                            |
| A83.0                     | Japanese encephalitis  |
| A83.1                     | Western equine encephalitis  |
| A83.2                     | Eastern equine encephalitis  |
| A83.3                     | St Louis encephalitis  |
| A83.4                     | Australian encephalitis  |
| A83.5                     | California encephalitis  |
| A83.6                     | Rocio virus disease  |
| A83.8                     | Other mosquito-borne viral encephalitis                                  |
| A84.0                     | Far Eastern tick-borne encephalitis [Russian spring-summer encephalitis] |
| A84.1                     | Central European tick-borne encephalitis                                 |

## MEDICAL POLICY

|                      |                                 |
|----------------------|---------------------------------|
| <b>POLICY TITLE</b>  | <b>EVOKED POTENTIAL STUDIES</b> |
| <b>POLICY NUMBER</b> | <b>MP 4.029</b>                 |

| <b>ICD-10-CM<br/>Diagnosis<br/>Codes</b> | <b>Description</b>  |
|--|---|
| A84.81                                   | Powassan virus disease  |
| A84.89                                   | Other tick-borne viral encephalitis   |
| A84.9                                    | Tick-borne viral encephalitis, unspecified  |
| A85.2                                    | Arthropod-borne viral encephalitis, unspecified   |
| B00.4                                    | Herpes viral encephalitis   |
| B00.82                                   | Herpes simplex myelitis   |
| B02.24                                   | Postherpetic myelitis   |
| B05.0                                    | Measles complicated by encephalitis   |
| B06.01                                   | Rubella encephalitis  |
| C41.2                                    | Malignant neoplasm of vertebral column  |
| C70.0                                    | Malignant neoplasm of cerebral meninges   |
| C70.1                                    | Malignant neoplasm of spinal meninges   |
| C72.0                                    | Malignant neoplasm of spinal cord   |
| C72.1                                    | Malignant neoplasm of cauda equina  |
| C79.40                                   | Secondary malignant neoplasm of unspecified part of nervous system                      |
| D32.1                                    | Benign neoplasm of spinal meninges  |
| D33.3                                    | Benign neoplasm of cranial nerves   |
| D33.4                                    | Benign neoplasm of spinal cord  |
| D42.1                                    | Neoplasm of uncertain behavior of spinal meninges                                       |
| D42.9                                    | Neoplasm of uncertain behavior of meninges, unspecified                                 |
| D43.9                                    | Neoplasm of uncertain behavior of cranial nerves  |
| G06.1                                    | Intraspinal abscess and granuloma   |
| G11.0                                    | Congenital nonprogressive ataxia  |
| G11.1                                    | Early-onset cerebellar ataxia   |
| G11.10                                   | Early-onset cerebellar ataxia, unspecified  |
| G11.11                                   | Friedreich ataxia   |
| G11.19                                   | Other early-onset cerebellar ataxia   |
| G11.2                                    | Late-onset cerebellar ataxia  |
| G11.3                                    | Cerebellar ataxia with defective DNA repair   |
| G11.4                                    | Hereditary spastic paraplegia   |
| G11.6                                    | Leukodystrophy with vanishing white matter disease                                      |
| G11.8                                    | Other hereditary ataxias  |
| G13.0                                    | Paraneoplastic neuromyopathy and neuropathy   |
| G13.1                                    | Other systemic atrophy primarily affecting central nervous system in neoplastic disease |

## MEDICAL POLICY

|                      |                                 |
|----------------------|---------------------------------|
| <b>POLICY TITLE</b>  | <b>EVOKED POTENTIAL STUDIES</b> |
| <b>POLICY NUMBER</b> | <b>MP 4.029</b>                 |

| <b>ICD-10-CM<br/>Diagnosis<br/>Codes</b> | <b>Description</b>   |
|--|--|
| G23.0                                    | Hallervorden-Spatz disease   |
| G23.1                                    | Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]       |
| G23.2                                    | Striatonigral degeneration   |
| G23.3                                    | Hypomyelination with atrophy of the basal ganglia and cerebellum             |
| G23.8                                    | Other specified degenerative diseases of basal ganglia                       |
| G25.3                                    | Myoclonus  |
| G31.80                                   | Leukodystrophy, unspecified  |
| G32.81                                   | Cerebellar ataxia in diseases classified elsewhere                           |
| G35                                      | Multiple sclerosis   |
| G35A                                     | Relapsing-remitting multiple sclerosis                                       |
| G35B                                     | Primary progressive multiple sclerosis                                       |
| G35B0                                    | Primary progressive multiple sclerosis, unspecified                          |
| G35B1                                    | Active primary progressive multiple sclerosis                                |
| G35B2                                    | Non-active primary progressive multiple sclerosis                            |
| G35C                                     | Secondary progressive multiple sclerosis                                     |
| G35C0                                    | Secondary progressive multiple sclerosis, unspecified                        |
| G35C1                                    | Active secondary progressive multiple sclerosis                              |
| G35C2                                    | Non-active secondary progressive multiple sclerosis                          |
| G35D                                     | Multiple sclerosis, unspecified  |
| G36.0                                    | Neuromyelitis optica [Devic]   |
| G36.1                                    | Acute and subacute hemorrhagic leukoencephalitis [Hurst]                     |
| G36.8                                    | Other specified acute disseminated demyelination                             |
| G37.0                                    | Diffuse sclerosis of central nervous system                                  |
| G37.1                                    | Central demyelination of corpus callosum                                     |
| G37.2                                    | Central pontine myelinolysis   |
| G37.3                                    | Acute transverse myelitis in demyelinating disease of central nervous system |
| G37.4                                    | Subacute necrotizing myelitis of central nervous system                      |
| G37.5                                    | Concentric sclerosis [Balo] of central nervous system                        |
| G37.8                                    | Other specified demyelinating diseases of central nervous system             |
| G37.81                                   | Myelin oligodendrocyte glycoprotein antibody disease                         |
| G37.89                                   | Other specified demyelinating diseases of central nervous system             |
| G62.9                                    | Polyneuropathy, unspecified  |
| G90.B                                    | LMNB1-related autosomal dominant leukodystrophy                              |
| G92.8                                    | Other toxic encephalopathy   |
| G92.9                                    | Unspecified toxic encephalopathy   |

## MEDICAL POLICY

|                      |                                 |
|----------------------|---------------------------------|
| <b>POLICY TITLE</b>  | <b>EVOKED POTENTIAL STUDIES</b> |
| <b>POLICY NUMBER</b> | <b>MP 4.029</b>                 |

| <b>ICD-10-CM Diagnosis Codes</b> | <b>Description</b>  |
|----------------------------------|---|
| G93.1                            | Anoxic brain damage, not elsewhere classified               |
| G93.42                           | Megaloencephalic leukoencephalopathy with subcortical cysts |
| G93.43                           | Leukoencephalopathy with calcifications and cysts           |
| G93.44                           | Adult-onset leukodystrophy with axonal spheroids            |
| G93.82                           | Brain death   |
| G95.0                            | Syringomyelia and syringobulbia                             |
| G95.11                           | Acute infarction of spinal cord (embolic) (nonembolic)      |
| G95.19                           | Other vascular myelopathies                                 |
| G95.81                           | Conus medullaris syndrome                                   |
| G95.89                           | Other specified diseases of spinal cord                     |
| P91.63                           | Severe hypoxic ischemic encephalopathy [HIE]                |
| R20.0                            | Anesthesia of skin  |
| R20.2                            | Paresthesia of skin   |
| R29.2                            | Abnormal reflex   |
| R40.20                           | Unspecified coma  |

### Covered when medically necessary Visual Evoked Potentials:

| <b>Procedure Codes</b> |  |  |  |  |  |  |  |
|------------------------|--|--|--|--|--|--|--|
| 95930                  |  |  |  |  |  |  |  |

| <b>ICD-10-CM Diagnosis Codes</b> | <b>Description</b>                   |
|----------------------------------|--------------------------------------|
| G35                              | Multiple sclerosis                   |
| H46.01                           | Optic papillitis, right eye          |
| H46.02                           | Optic papillitis, left eye           |
| H46.03                           | Optic papillitis, bilateral          |
| H46.11                           | Retrobulbar neuritis, right eye      |
| H46.12                           | Retrobulbar neuritis, left eye       |
| H46.13                           | Retrobulbar neuritis, bilateral      |
| H46.2                            | Nutritional optic neuropathy         |
| H46.3                            | Toxic optic neuropathy               |
| H46.8                            | Other optic neuritis                 |
| H47.011                          | Ischemic optic neuropathy, right eye |
| H47.012                          | Ischemic optic neuropathy, left eye  |

**MEDICAL POLICY**

|                      |                                 |
|----------------------|---------------------------------|
| <b>POLICY TITLE</b>  | <b>EVOKED POTENTIAL STUDIES</b> |
| <b>POLICY NUMBER</b> | <b>MP 4.029</b>                 |

| <b>ICD-10-CM Diagnosis Codes</b> | <b>Description</b>  |
|----------------------------------|---|
| H47.013                          | Ischemic optic neuropathy, bilateral                                |
| H47.021                          | Hemorrhage in optic nerve sheath, right eye                         |
| H47.022                          | Hemorrhage in optic nerve sheath, left eye                          |
| H47.023                          | Hemorrhage in optic nerve sheath, bilateral                         |
| H47.031                          | Optic nerve hypoplasia, right eye                                   |
| H47.032                          | Optic nerve hypoplasia, left eye                                    |
| H47.033                          | Optic nerve hypoplasia, bilateral                                   |
| H47.091                          | Other disorders of optic nerve, not elsewhere classified, right eye |
| H47.092                          | Other disorders of optic nerve, not elsewhere classified, left eye  |
| H47.093                          | Other disorders of optic nerve, not elsewhere classified, bilateral |
| H47.11                           | Papilledema associated with increased intracranial pressure         |
| H47.12                           | Papilledema associated with decreased ocular pressure               |
| H47.13                           | Papilledema associated with retinal disorder                        |
| H47.141                          | Foster-Kennedy syndrome, right eye                                  |
| H47.142                          | Foster-Kennedy syndrome, left eye                                   |
| H47.143                          | Foster-Kennedy syndrome, bilateral                                  |
| H47.211                          | Primary optic atrophy, right eye                                    |
| H47.212                          | Primary optic atrophy, left eye                                     |
| H47.213                          | Primary optic atrophy, bilateral                                    |
| H47.231                          | Glaucomatous optic atrophy, right eye                               |
| H47.232                          | Glaucomatous optic atrophy, left eye                                |
| H47.233                          | Glaucomatous optic atrophy, bilateral                               |
| H47.291                          | Other optic atrophy, right eye                                      |
| H47.292                          | Other optic atrophy, left eye                                       |
| H47.293                          | Other optic atrophy, bilateral                                      |
| H47.311                          | Coloboma of optic disc, right eye                                   |
| H47.312                          | Coloboma of optic disc, left eye                                    |
| H47.313                          | Coloboma of optic disc, bilateral                                   |
| H47.321                          | Drusen of optic disc, right eye                                     |
| H47.322                          | Drusen of optic disc, left eye                                      |
| H47.323                          | Drusen of optic disc, bilateral                                     |
| H47.331                          | Pseudopapilledema of optic disc, right eye                          |
| H47.332                          | Pseudopapilledema of optic disc, left eye                           |
| H47.333                          | Pseudopapilledema of optic disc, bilateral                          |

**MEDICAL POLICY**

|                      |                                 |
|----------------------|---------------------------------|
| <b>POLICY TITLE</b>  | <b>EVOKED POTENTIAL STUDIES</b> |
| <b>POLICY NUMBER</b> | <b>MP 4.029</b>                 |

| <b>ICD-10-CM Diagnosis Codes</b> | <b>Description</b>   |
|----------------------------------|--|
| H47.391                          | Other disorders of optic disc, right eye   |
| H47.392                          | Other disorders of optic disc, left eye  |
| H47.393                          | Other disorders of optic disc, bilateral   |
| H47.41                           | Disorders of optic chiasm in (due to) inflammatory disorders                       |
| H47.42                           | Disorders of optic chiasm in (due to) neoplasm                                     |
| H47.43                           | Disorders of optic chiasm in (due to) vascular disorders                           |
| H47.49                           | Disorders of optic chiasm in (due to) other disorders                              |
| H47.511                          | Disorders of visual pathways in (due to) inflammatory disorders, right side        |
| H47.512                          | Disorders of visual pathways in (due to) inflammatory disorders, left side         |
| H47.521                          | Disorders of visual pathways in (due to) neoplasm, right side                      |
| H47.522                          | Disorders of visual pathways in (due to) neoplasm, left side                       |
| H47.531                          | Disorders of visual pathways in (due to) vascular disorders, right side            |
| H47.532                          | Disorders of visual pathways in (due to) vascular disorders, left side             |
| H47.611                          | Cortical blindness, right side of brain  |
| H47.612                          | Cortical blindness, left side of brain   |
| H47.621                          | Disorders of visual cortex in (due to) inflammatory disorders, right side of brain |
| H47.622                          | Disorders of visual cortex in (due to) inflammatory disorders, left side of brain  |
| H47.631                          | Disorders of visual cortex in (due to) neoplasm, right side of brain               |
| H47.632                          | Disorders of visual cortex in (due to) neoplasm, left side of brain                |
| H47.641                          | Disorders of visual cortex in (due to) vascular disorders, right side of brain     |
| H47.642                          | Disorders of visual cortex in (due to) vascular disorders, left side of brain      |
| H53.011                          | Deprivation amblyopia, right eye   |
| H53.012                          | Deprivation amblyopia, left eye  |
| H53.013                          | Deprivation amblyopia, bilateral   |
| H53.021                          | Refractive amblyopia, right eye  |
| H53.022                          | Refractive amblyopia, left eye   |
| H53.023                          | Refractive amblyopia, bilateral  |
| H53.031                          | Strabismic amblyopia, right eye  |
| H53.032                          | Strabismic amblyopia, left eye   |
| H53.033                          | Strabismic amblyopia, bilateral  |
| H53.11                           | Day blindness  |
| H53.121                          | Transient visual loss, right eye   |
| H53.122                          | Transient visual loss, left eye  |
| H53.123                          | Transient visual loss, bilateral   |

**MEDICAL POLICY**

|                      |                                 |
|----------------------|---------------------------------|
| <b>POLICY TITLE</b>  | <b>EVOKED POTENTIAL STUDIES</b> |
| <b>POLICY NUMBER</b> | <b>MP 4.029</b>                 |

| <b>ICD-10-CM Diagnosis Codes</b> | <b>Description</b>                                 |
|----------------------------------|--|
| H53.131                          | Sudden visual loss, right eye                      |
| H53.132                          | Sudden visual loss, left eye                       |
| H53.133                          | Sudden visual loss, bilateral                      |
| H53.141                          | Visual discomfort, right eye                       |
| H53.142                          | Visual discomfort, left eye                        |
| H53.143                          | Visual discomfort, bilateral                       |
| H53.15                           | Visual distortions of shape and size               |
| H53.16                           | Psychophysical visual disturbances                 |
| H53.19                           | Other subjective visual disturbances               |
| H53.2                            | Diplopia   |
| H53.31                           | Abnormal retinal correspondence                    |
| H53.32                           | Fusion with defective stereopsis                   |
| H53.33                           | Simultaneous visual perception without fusion      |
| H53.34                           | Suppression of binocular vision                    |
| H53.411                          | Scotoma involving central area, right eye          |
| H53.412                          | Scotoma involving central area, left eye           |
| H53.413                          | Scotoma involving central area, bilateral          |
| H53.421                          | Scotoma of blind spot area, right eye              |
| H53.422                          | Scotoma of blind spot area, left eye               |
| H53.423                          | Scotoma of blind spot area, bilateral              |
| H53.431                          | Sector or arcuate defects, right eye               |
| H53.432                          | Sector or arcuate defects, left eye                |
| H53.433                          | Sector or arcuate defects, bilateral               |
| H53.451                          | Other localized visual field defect, right eye     |
| H53.452                          | Other localized visual field defect, left eye      |
| H53.453                          | Other localized visual field defect, bilateral     |
| H53.461                          | Homonymous bilateral field defects, right side     |
| H53.462                          | Homonymous bilateral field defects, left side      |
| H53.47                           | Heteronymous bilateral field defects               |
| H53.481                          | Generalized contraction of visual field, right eye |
| H53.482                          | Generalized contraction of visual field, left eye  |
| H53.483                          | Generalized contraction of visual field, bilateral |
| H53.51                           | Achromatopsia                                      |
| H53.52                           | Acquired color vision deficiency                   |

## MEDICAL POLICY

|                      |                                 |
|----------------------|---------------------------------|
| <b>POLICY TITLE</b>  | <b>EVOKED POTENTIAL STUDIES</b> |
| <b>POLICY NUMBER</b> | <b>MP 4.029</b>                 |

| <b>ICD-10-CM Diagnosis Codes</b> | <b>Description</b>              |
|----------------------------------|---------------------------------|
| H53.53                           | Deuteranomaly                   |
| H53.54                           | Protanomaly                     |
| H53.55                           | Tritanomaly                     |
| H53.59                           | Other color vision deficiencies |
| H53.61                           | Abnormal dark adaptation curve  |
| H53.62                           | Acquired night blindness        |
| H53.63                           | Congenital night blindness      |
| H53.69                           | Other night blindness           |
| H53.71                           | Glare sensitivity               |
| H53.72                           | Impaired contrast sensitivity   |
| H53.8                            | Other visual disturbances       |

### REFERENCES

1. American Clinical Neurophysiological Society (ACNS). *Guideline 9A: Guidelines on Evoked Potentials*. February 2006
2. American Clinical Neurophysiological Society (ACNS). *Guideline 9B: Guidelines on Visual Evoked Potentials*. February 2008
3. American Clinical Neurophysiological Society (ACNS). *Guideline 9C: Guidelines on Short-Latency Auditory Evoked Potentials*. 2008
4. American Clinical Neurophysiological Society (ACNS). *Guideline 9D: Guidelines on Short-Latency Somatosensory Evoked Potentials*. February 2006
5. Evans, A. *Clinical Utility of Evoked Potentials* eMedicine updated 01/25/2019 eMedicine
6. NICE Guidance *Glaucoma: Diagnosis and management* November 2017; last updated January 2022
7. Pillai C, Ritch R, et al. *Sensitivity and Specificity of Short Duration Transient Visual Evoked Potential (SD-tVEP) in Discrimination Normal From Glaucomatous Eyes*. *Invest. Ophthalmol. Vis. Sci.* April 23, 2013 vol. 54 no. 4 2847-2852
8. Olek M. *Evaluation and diagnosis of multiple sclerosis in adults*. In: *UpToDate Online Journal* [serial online]. Waltham, MA: UpToDate; updated April 30, 2024
9. Weinhouse G., Young, B.. *Hypoxic-ischemic brain injury in adults: Evaluation and prognosis*. *UpToDate Online Journal* [serial online]. Waltham, MA: UpToDate; updated May 22, 2024
10. American Association of Neuromuscular & Electrodiagnostic Medicine. *Somatosensory Evoked Potentials: Clinical Uses*.

**MEDICAL POLICY**

|                      |                                 |
|----------------------|---------------------------------|
| <b>POLICY TITLE</b>  | <b>EVOKED POTENTIAL STUDIES</b> |
| <b>POLICY NUMBER</b> | <b>MP 4.029</b>                 |

**POLICY HISTORY**

|                 |  |
|-----------------|--|
| <b>MP 4.029</b> | <b>07/17/2020 Consensus Review.</b> No changes to the policy statements. References reviewed.  |
|                 | <b>06/17/2020 Consensus Review.</b> No change to policy statements. References updated. Rationale updated to include the updated NICE guidelines.                                    |
|                 | <b>05/19/2021 Consensus Review.</b> No change to policy statements. References updated. Coding updated 92585 and 92586 were deleted and replaced with 92650-92653. Dx coding updated |
|                 | <b>09/07/2021 Administrative Update.</b> New codes G44.86 and G92.9 added. Effective 10/01/2021  |
|                 | <b>03/18/2022 Minor Review.</b> Deleted MN criteria and codes on brainstem auditory testing. Updated FEP, background, ICD-10 table, and references.                                  |
|                 | <b>08/03/2023 Consensus Review.</b> No changes to policy language or intent.   |
|                 | <b>01/19/2024 Administrative Update.</b> Clinical benefit added.   |
|                 | <b>01/08/2025 Consensus Review.</b> No change to policy statement. References updated.   |
|                 | <b>09/03/2025 Administrative Update.</b> New ICD-10 codes added as part of new code for 10/01/2025   |
|                 | <b>09/08/2025 Administrative Update.</b> Removed Benefit Variations Section and updated Disclaimer.  |
|                 | <b>10/31/2025 Consensus Review.</b> No change to policy statement. References updated.   |

*Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company®, and Keystone Health Plan® Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.*